Daniel D. Burton Acquires 49,050 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) CEO Daniel D. Burton bought 49,050 shares of Health Catalyst stock in a transaction on Friday, May 12th. The stock was acquired at an average price of $10.19 per share, for a total transaction of $499,819.50. Following the transaction, the chief executive officer now directly owns 919,415 shares of the company’s stock, valued at $9,368,838.85. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT opened at $10.36 on Friday. The business’s fifty day moving average price is $12.17 and its two-hundred day moving average price is $11.64. The stock has a market cap of $582.85 million, a PE ratio of -3.89 and a beta of 1.23. The company has a debt-to-equity ratio of 0.53, a quick ratio of 5.18 and a current ratio of 5.18. Health Catalyst, Inc. has a one year low of $6.40 and a one year high of $18.30.

Health Catalyst (NASDAQ:HCAT – Get Rating) last announced its earnings results on Tuesday, February 28th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. The firm had revenue of $69.16 million for the quarter, compared to analysts’ expectations of $68.37 million. Health Catalyst had a negative return on equity of 18.98% and a negative net margin of 49.74%. On average, analysts forecast that Health Catalyst, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Guggenheim downgraded Health Catalyst from a “buy” rating to a “neutral” rating in a research report on Wednesday. Stephens initiated coverage on Health Catalyst in a research note on Tuesday, April 11th. They issued an “equal weight” rating and a $13.00 price objective for the company. Royal Bank of Canada lifted their price target on Health Catalyst from $9.00 to $15.00 and gave the stock a “sector perform” rating in a report on Wednesday, March 1st. Wells Fargo & Company raised Health Catalyst from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $13.00 to $16.00 in a report on Tuesday, April 4th. Finally, Raymond James downgraded Health Catalyst from an “outperform” rating to a “market perform” rating in a report on Wednesday. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Health Catalyst has a consensus rating of “Hold” and a consensus target price of $15.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HCAT. Advisor Group Holdings Inc. lifted its stake in shares of Health Catalyst by 86.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 5,324 shares of the company’s stock worth $137,000 after purchasing an additional 2,467 shares during the period. Fairfield Bush & CO. acquired a new position in Health Catalyst in the first quarter worth about $25,000. Raymond James Financial Services Advisors Inc. grew its stake in Health Catalyst by 118.6% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 11,157 shares of the company’s stock worth $292,000 after purchasing an additional 6,053 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Health Catalyst by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 750,396 shares of the company’s stock worth $19,607,000 after purchasing an additional 35,022 shares in the last quarter. Finally, US Bancorp DE grew its stake in Health Catalyst by 14.0% in the first quarter. US Bancorp DE now owns 9,260 shares of the company’s stock worth $242,000 after purchasing an additional 1,139 shares in the last quarter. Hedge funds and other institutional investors own 90.55% of the company’s stock.

About Health Catalyst

(Get Rating)

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.